

24th Annual
**International
Lung Cancer
CONGRESS®**

Scan here to
engage with
content and
presenters in
real time!



JULY 27–29, 2023

PROGRAM CHAIRS

David R. Gandara, MD
Roy S. Herbst, MD, PhD
Heather A. Wakelee, MD, FASCO



For more information, visit us at...

[gotoper.com](https://www.gotoper.com)

STAY CONNECTED! Follow us @GoToPER and share
your thoughts and photos by using #GoToPER.



WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC, (PER®), and the planning committee, we would like to welcome you and to thank you for choosing to attend the **24th Annual International Lung Cancer Congress**.

On day one, we will review the latest developments in immunotherapy and targeted agents for stage I-III non-small cell lung cancer (NSCLC), including perioperative immunotherapy for resectable disease. On day two, David P. Carbone, MD, PhD, will deliver the Annual Addario Foundation Keynote Lecture on what we can expect during the next decade of lung cancer research. Additionally, Roy S. Herbst, MD, PhD, will discuss a long-term perspective on treatment of NSCLC from targeted therapy to immunotherapy, including future therapeutic approaches, during the Giants of Cancer Care® Keynote Lecture on day three.

Sessions will be held every day on state-of-the-art approaches for immunotherapy and targeted therapies in stage IV NSCLC and best practices in thymic malignancies, mesothelioma, and small cell lung cancer. There will also be talks dedicated to targeted therapies for oncogenic drivers and emerging classes of agents such as antibody-drug conjugates. Finally, case-based panels and Q&A exchanges throughout the meeting will teach you how to integrate the latest data into clinical practice.

In working together with PER, we strive to make this activity, along with all of PER's accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved in the care of patients with lung cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of lung cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER congress, and that you can attend another PER accredited CE activity soon.

Regards,

David R. Gandara, MD

Chief Medical Officer, International Society of Liquid Biopsy
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
UC Davis Health Comprehensive Cancer Center
Adjunct Clinical Professor, Translational and Clinical Research Program
Professor Emeritus
University of Hawaii Cancer Center
Sacramento, CA

Roy S. Herbst, MD, PhD

Deputy Director, Chief of Medical Oncology
Director, Center for Thoracic Cancers
Yale Cancer Center and Smilow Cancer Hospital
Assistant Dean for Translational Research
Ensign Professor of Medicine
Professor of Pharmacology
Yale School of Medicine
New Haven, CT

Heather A. Wakelee, MD, FASCO

Interim Medical Director, Deputy Director
Stanford Cancer Institute
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
President, International Association for the
Study of Lung Cancer
Stanford, CA

Jim Palatine, RPh, MBA

President
Physicians' Education Resource, LLC
Cranbury, NJ
jpalatine@mjhlifesciences.com

AGENDA

All times US PDT

Thursday, July 28		
7:15 AM	Non-CE Breakfast: The Evolving Role of Biomarkers in Advanced NSCLC <i>Sponsored by Sanofi</i>	Hatim Husain, MD
8:30 AM	Welcome, Introductions, and Pre-session Survey	
Early-Stage NSCLC		Moderator: Heather A. Wakelee, MD, FASCO
8:45 AM	Update on Early-Stage, Driver Mutation-Positive NSCLC	Masahiro Tsuboi, MD
9:00 AM	Update on Early-Stage Perioperative Immunotherapy Trials in NSCLC	Heather A. Wakelee, MD, FASCO
9:15 AM	Update on Radiation Therapy Trials in Early-Stage NSCLC	Megan E. Daly, MD
9:30 AM	Update on Surgical Considerations in Early-Stage NSCLC	Leah M. Backhus, MD, MPH, FACS
9:45 AM	Panel Discussion: Most Relevant Patient and Tumor Factors for Therapeutic Decision-Making in Early-Stage NSCLC	David T. Cooke, MD, FACS Roy S. Herbst, MD, PhD; Natasha B. Leighl, MD, MMSc, FRCPC, FASCO; Solange Peters, MD, PhD; Heather A. Wakelee, MD, FASCO Leah M. Backhus, MD, MPH, FACS; Masahiro Tsuboi, MD; Megan E. Daly, MD; Maria E. Arcila, MD
10:00 AM	Break	
Tumor Board in Early-Stage and Locally Advanced NSCLC		Moderator: Karen Kelly, MD
10:25 AM	Multidisciplinary Tumor Board (Stage I-III NSCLC) <ul style="list-style-type: none"> • Stage IB, EGFR Mutated • Stage II Neoadjuvant vs Adjuvant vs Both • Stage IIIB, Borderline Resectable 	Maria E. Arcila, MD; Leah M. Backhus, MD, MPH, FACS; Hossein Borghaei, DO, MS; David T. Cooke, MD, FACS; Megan E. Daly, MD; Fred R. Hirsch, MD, PhD Corey J. Langer, MD, FACP; Erminia Massarelli, MD, PhD, MS; Nicholas Stollenwerk, MD
11:55 AM	Postsession Survey	
12:00 PM	Treatment of Unresectable Stage III NSCLC and ES-SCLC & A Treatment Option for Patients With Resectable and Metastatic NSCLC <i>Sponsored by AstraZeneca</i>	Hatim Husain, MD
1:15 PM	Pre-session Survey	
Mini Symposium on Utilization of Liquid Biopsy in NSCLC		Moderator: Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
1:20 PM	Role of the Molecular Pathologist in Tissue-Liquid Biopsy	Maria E. Arcila, MD
1:30 PM	Complementary Application of Tissue and Liquid Biopsy for Molecular Testing	Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
1:40 PM	Role of Liquid Biopsy for Immunotherapy in NSCLC, Including MRD	David R. Gandara, MD
1:50 PM	Panel Discussion	Maria E. Arcila, MD; Hatim Husain, MD; David R. Gandara, MD; Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Acquired Resistance in Oncogene-Driven NSCLC: Empirical Treatment Decision-Making vs Precision Medicine Approaches		Moderator: David R. Gandara, MD
2:05 PM	Panel Discussion	Lyudmila Bazhenova, MD; Deborah Doroshow, MD, PhD; Pasi A. Jänne, MD, PhD; Jyoti Malhotra, MD, MPH Edgardo S. Santos Castillero, MD, FACP
2:45 PM	Break	

AGENDA

Addressing Disparities in Care		Moderator: Narjust Florez, MD
3:10 PM	What Can You Do to Reach a More Diverse Patient Population and Help Overcome Barriers?	Narjust Florez, MD
3:25 PM	Changes in Clinical Trial Designs to Improve Representation (Pragmatic Trial Designs and Real-World Data)	Edward Kim, MD, MBA, FACP, FASCO
Targeted Agents Workshop: Oncogenic Fusions		Moderator: Edgardo S. Santos Castellero, MD, FACP
3:40 PM	ALK	Hatim Husain, MD
3:47 PM	NRG	Edgardo S. Santos Castellero, MD, FACP
3:54 PM	NTRK	Erminia Massarelli, MD, PhD, MS
4:01 PM	RET	Deborah Doroshov, MD, PhD
4:08 PM	ROS1	Misako Nagasaka, MD
4:15 PM	Panel Discussion	Deborah Doroshov, MD, PhD; Fred R. Hirsch, MD, PhD; Hatim Husain, MD; Erminia Massarelli, MD, PhD, MS; Misako Nagasaka, MD; Edgardo S. Santos Castellero, MD, FACP
Resistance to Immunotherapy		Moderator: Solange Peters, MD, PhD
4:35 PM	Patient and Tumor Characteristics Conducive to Immunotherapy in First-Line NSCLC	Hossein Borghaei, DO, MS
4:50 PM	The Mechanisms of Resistance to Immunotherapy and How to Overcome Them	Solange Peters, MD, PhD
5:05 PM	Panel Discussion: What to Do at the Time of Acquired Resistance to ICI Therapy	Paul Baas, MD, PhD; Hossein Borghaei, DO, MS; David P. Carbone, MD, PhD; David R. Gandara, MD; Jyoti Malhotra, MD, MPH; Solange Peters, MD, PhD; Heather A. Wakelee, MD, FASCO
5:20 PM	Postsession Survey	
5:25 PM	Adjournment	
5:30 PM	Welcome Reception in the Exhibit Hall	
Friday, July 28		
7:15 AM	Non-CE Breakfast: Personalizing Treatment for Adult Patients with Advanced NSCLC <i>Sponsored by Regeneron</i>	Martin Dietrich, MD, PhD
8:30 AM	Welcome, Introductions, and Pre-session Survey	
Small Cell Lung Cancer (SCLC)		Moderator: Millie Das, MD
8:45 AM	What to Do After Resistance to First-Line Immunotherapy in SCLC	Primo N. Lara Jr, MD
9:00 AM	New Drugs for SCLC (Including New Antibodies)	Millie Das, MD
9:15 AM	Panel Discussion: What to Do in Limited SCLC After Failure of PE/RT	Millie Das, MD; Corey J. Langer, MD, FACP; Primo N. Lara Jr, MD
16th Annual Addario Keynote Lecture		Chairs: David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO
9:25 AM	Introduction	
9:35 AM	What's Next in Lung Cancer?	David P. Carbone, MD, PhD
10:05 AM	Q&A Session	
10:10 AM	Break	

AGENDA

Other Thoracic Malignancies		Moderator: Paul Baas, MD, PhD
10:35 AM	Mesothelioma: Latest Updates, Including Immunotherapy	Paul Baas, MD, PhD
10:50 AM	Thymic Malignancies: Novel Therapeutics	Heather A. Wakelee, MD, FASCO
11:05 AM	Multidisciplinary Tumor Board: Other Thoracic Malignancies (Mesothelioma, Early-Stage Thymoma, Thymic Carcinoma)	Leah M. Backhus MD, MPH, FACS; David T. Cooke, MD, FACS; Masahiro Tsuboi, MD Megan E. Daly, MD; Nicholas Stollenwerk, MD; Maria E. Arcila, MD; Karen Kelly, MD; Misako Nagasaka, MD
12:05 PM	Postsession Survey	
12:10 PM	Non-CE Lunch Symposium - Precision Oncology for Patients with RET-Positive NSCLC <i>Sponsored by Lilly</i>	Martin Dietrich, MD, PhD
1:25 PM	Presession Survey	
Targeted Agents Workshop: Oncogenic Mutations		Moderator: Lyudmila Bazhenova, MD
1:30 PM	EGFR Common Mutations	Pasi A. Jänne, MD, PhD
1:37 PM	EGFR Exon 20	Edgardo S. Santos Castellero, MD, FACP
1:44 PM	HER2	Lyudmila Bazhenova, MD
1:51 PM	Panel Discussion	Lyudmila Bazhenova, MD; Jonathan Goldman, MD; Pasi A. Jänne, MD, PhD; Corey J. Langer, MD, FACP; Karen L. Reckamp, MD; Edgardo S. Santos Castellero, MD, FACP; Heather A. Wakelee, MD
2:10 PM	BRAF V600E and Beyond	Corey J. Langer, MD, FACP
2:17 PM	KRAS G12C and Beyond	Lyudmila Bazhenova, MD
2:24 PM	MET Exon 14	Jonathan Goldman, MD
2:31 PM	Panel Discussion	Lyudmila Bazhenova, MD; Jonathan Goldman, MD; Pasi A. Jänne, MD, PhD; Corey J. Langer, MD, FACP; Karen L. Reckamp, MD; Edgardo S. Santos Castellero, MD, FACP; Heather A. Wakelee, MD, FASCO
2:50 PM	Break	
First-Line Immunotherapy		Moderator: Hossein Borghaei, DO, MS
3:15 PM	Case-Based Discussion: How Do You Choose a First-Line Option in Stage IV NSCLC (IO Alone vs IO+IO vs Chemo+IO)?	Hossein Borghaei, DO, MS; David P. Carbone, MD, PhD; Millie Das, MD; Jonathan Goldman, MD; Edward Kim, MD, MBA, FACP, FASCO; Natasha B. Leighl, MD, MMSc, FRCPC, FASCO; Erminia Massarelli, MD, PhD, MS; Tony S. Mok, MD, FRCPC, FASCO; Solange Peters, MD, PhD
Managing Oligometastases		Moderator Narjust Florez, MD
4:05 PM	Challenging Cases of Oligometastases (Brain Metastases, Liver Metastases, Other Oligometastatic Cases)	Megan E. Daly, MD Leah M. Backhus, MD, MPH, FACS; David T. Cooke, MD, FACS Deborah Doroshov, MD, PhD; Corey J. Langer, MD, FACP; Primo N. Lara Jr, MD
4:55 PM	Postsession Survey	
5:00 PM	Adjournment	

AGENDA

5:00 PM Get Acquainted Reception in the Exhibit Hall

Saturday, July 29

7:15 AM Breakfast

8:30 AM Welcome, Introductions, and Pre-session Survey

Keynote Lecture: Giants of Cancer Care®

Chairs: David R. Gandara, MD,
and Heather A. Wakelee, MD, FASCO

8:45 AM Twenty Years of Progress in the Treatment of NSCLC From Targeted Therapy to Immunotherapy: What Does the Future Hold?

Roy S. Herbst, MD, PhD

Antibody-Drug Conjugates

Moderator: Karen L. Reckamp, MD

9:15 AM ADCs: New Agents and Targets in Development

Karen L. Reckamp, MD

9:30 AM Roundtable Discussion: Biomarkers for and Applications of ADCs

Maria E. Arcila, MD; Narjust Florez, MD;
Karen L. Reckamp, MD; FACP, FASCO

10:00 AM Break

Immunotherapy: Challenges and Future Directions

Moderator: Corey J. Langer, MD, FACP

10:25 AM What Is Coming in Immunotherapy?

Tony S. Mok, MD, FRCPC, FASCO

10:40 AM Panel Discussion on irAEs: When Do You Need the Subspecialists to Optimize Care?

Millie Das, MD; Narjust Florez, MD;
Erminia Massarelli, MD, PhD, MS;
Nicholas Stollenwerk, MD

Moving Forward in Advanced Stage NSCLC

Chairs: David R. Gandara, MD; Roy S. Herbst,
MD, PhD; Heather A. Wakelee, MD, FASCO

10:55 AM Panel Discussion: What Are Your Key Take-Home Points for Advanced Stage NSCLC in 2023?

David P. Carbone, MD, PhD;
David R. Gandara, MD;
Roy S. Herbst, MD, PhD;
Solange Peters, MD, PhD;
Heather A. Wakelee, MD, FASCO

11:55 AM Post-session Survey

12:00 PM Adjournment



Physicians' Education Resource®, LLC would like to acknowledge the GO2 Foundation for Lung Cancer for their support of the **24th Annual International Lung Cancer Congress®**.



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

Physicians' Education Resource®, LLC would also like to acknowledge the International Association for the Study of Lung Cancer as an endorser of the **24th Annual International Lung Cancer Congress®**.

ACTIVITY OVERVIEW

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Explain biomarkers and testing strategies to optimize selection of therapy in patients with thoracic malignancies
- Discuss emerging evidence concerning the management of patients with non-metastatic lung cancer
- Apply recent clinical data on single-agent and combination immunotherapeutic approaches to care for patients with advanced thoracic malignancies
- Review recent data sets on targeted and cytotoxic strategies for the management of patients with thoracic malignancies
- Summarize optimal and personalized strategies for sequencing therapy utilizing clinical trial evidence, performance status, and tumor characteristics
- Describe approaches to address variances in care for patients with thoracic malignancies

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER website by 12:00 PM EDT the next business day after the presentation. To access these materials, please visit <https://www.gotoper.com/ilc23-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit <https://www.gotoper.com/ilc23-eval>.

The online evaluation and the request for credit will be available by 12:00 PM EDT on July 31, 2023, and will remain available until September 14, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource, LLC, designates this live activity for a maximum of 16.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 16 Contact Hours

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Amgen Inc; AnHeart Therapeutics; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Daiichi Sankyo, Inc.; Exact Sciences; Genentech, a member of the Roche Group; Kinnate Biopharma, Inc.; Lilly; Merck & Co, Inc.; Novartis Pharmaceuticals Corporation; NovoCure, Inc.; Pfizer, Inc.; and Sanofi.

Thank you for attending the *24th Annual International Lung Cancer Congress*[®]
To register for upcoming accredited CE live activity
or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

Disclosures and Conflict of Interest (COI) Mitigation

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Karen Kelly, MD; Edward Kim, MD, MBA, FACP, FASCO; Primo N. Lara Jr, MD; Nicholas Stollenwerk, MD, and the staff of Physicians' Education Resource, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Maria E. Arcilla, MD		AstraZeneca, Bristol Myers Squibb, Janssen Global Services, Merck, Roche			Speaker fees: Biocartis
Paul Baas, MD, PhD	AstraZeneca, Bristol Myers Squibb				
	AstraZeneca, Bristol Myers Squibb, MSD, Takeda	Bristol Myers Squibb, MSD			
Leah M. Backhus MD, MPH, FACS			AstraZeneca		Advisory panel member for Genentech, Johnson & Johnson, Bristol Myers Squibb
Lyudmila Bazhenova, MD					
	AbbVie, AnHeart Therapeutics, Bayer, BioAtla, Daiichi Sankyo, Elevation Oncology, Genentech, Gilead Sciences, InterVenn Biosciences, Janssen, Merck, Mirati Therapeutics, Neuvogen, Novocure, ORIC Pharmaceuticals, Regeneron Pharmaceuticals, Turning Point Therapeutics		Epic Sciences		
Hossein Borghaei, DO, MS	Amgen, Bristol Myers Squibb, Eli Lilly and Company	Amgen, AstraZeneca, Axiom, Bayer, BeiGene, BerGenBio, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Da Volterra, Eli Lilly and Company, EMD Serono, Genentech, Genmab, Guardant Health, iTeos Therapeutics, Janssen, Jazz Pharmaceuticals, LobioTech, Merck, Mirati Therapeutics, Natera, Oncocyte, Novartis, Pfizer, PharmaMar, Puma Biotechnology, Regeneron Pharmaceuticals, Takeda	Honoraria: Amgen, Daiichi Sankyo, Pfizer, Regeneron Pharmaceuticals Travel: Amgen, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Genentech, Merck, Regeneron Pharmaceuticals	Sonnet BioTherapeutics Holdings (stock options), Inspirna (formerly Rgenix, stock options), Nucleai (stock options)	DSMB: University of Pennsylvania: CAR T Program, Takeda, Incyte, Novartis, SpringWorks Therapeutics
David P. Carbone, MD, PhD	AbbVie, Arcus Biosciences, AstraZeneca, Bristol Myers Squibb, Israel, EMD Serono, G1 Therapeutics, Genentech, GSK, lovance Biotherapeutics, Janssen, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi				
David T. Cooke, MD, FACS			Bristol Myers Squibb		Intuitive, Inc. (education support)

ACTIVITY OVERVIEW

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Megan E. Daly, MD	EMD Serono, Genentech, Merck	AstraZeneca, Boston Scientific, Novocure			Curio Science, Dava Oncology
Millie Das, MD	AbbVie, Celgene, CellSight Technologies, Genentech, Merck, Novartis, United Therapeutics, Varian, Verily	AstraZeneca, BeiGene, Bristol Myers Squibb (uncompensated), Eurofins, Genentech (uncompensated), Janssen, Regeneron Pharmaceuticals, Sanofi Genzyme			
Deborah Doroshow, MD, PhD	Conquer Cancer, the ASCO Foundation; Bristol Myers Squibb Foundation	Sonata Therapeutics; Ad boards: AstraZeneca, Mirati Therapeutics, G1 Therapeutics, Summit Therapeutics			
Narjust Florez, MD		AstraZeneca, DSI, Janssen, Merck, Mirati Therapeutics, Pfizer, Regeneron Pharmaceuticals	NeoGenomics		
David R. Gandara, MD	Amgen, Astex Pharmaceuticals, Genentech	Merck			Institutional: Adagene, AstraZeneca, Guardant Health, IO Biotech, Oncocyte, OncoHost, Roche/Genentech
Jonathan Goldman, MD	AbbVie, Adaxis, AstraZeneca, BMS, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, Spectrum, Vaccinex	AbbVie, AstraZeneca, BMS, Genentech, Gilead, Gritstone, Janssen, Jazz, Lilly, Pfizer, Puma, Regeneron			
Roy S. Herbst, MD, PhD	AstraZeneca, Eli Lilly and Company, Merck, Roche/Genentech	AbbVie, AstraZeneca, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Genentech, Gilead Sciences, HiberCell, I-Mab, Immune- Onc Therapeutics, Immunocore Holdings, Janssen Pharmaceutical Companies, Johnson & Johnson, Loxo Oncology, Mirati Therapeutics, NextCure, Novartis, Ocean Biomedical, Oncocyte, Oncternal Therapeutics, Pfizer, Regeneron Pharmaceuticals, Revelar Biotherapeutics, Ribon Therapeutics, Roche, Sanofi, Xencor			Board member (nonexecutive/ independent) : Immunocore Holdings, Junshi Pharmaceuticals
Fred R. Hirsch, MD, PhD		AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Genentech, Merus, Novartis, NextCure, Novocure, Regeneron Pharmaceuticals, Roche			
Pasi A. Jänne, MD, PhD	AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and Company, Puma Biotechnology, Revolution Medicines, Takeda	AbbVie, Accutar Biotechnology, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, DualityBio, Eli Lilly and Company, Esai, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa Therapeutics, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals Group, Silicon Therapeutics, Syndax Pharmaceuticals, Takeda, Transcenta Holding, Voronoi		Gatekeeper Pharmaceuticals	Patents: Labcorp, postmarketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp
Corey J. Langer, MD, FACP	Amgen, AstraZeneca, Eli Lilly and Company, Fujifilm, Incyte, INOVIO Pharmaceuticals, Janssen, Merck, Navire Pharma, Oncocyte, Takeda, Trizell	AstraZeneca, Boehringer Ingelheim, Gilead Sciences, GSK, Merck, Novocure, OncLive®, Pfizer, Regeneron Pharmaceuticals, Roche/Genentech, RTP, Sanofi, Takeda			Novartis and Medscape (medical writing support); DSMC: Oncocyte, VA (VALOR), RTOG Foundation

ACTIVITY OVERVIEW

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Natasha B. Leigh, MD, MMSc, FRCPC, FASCO	Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Guardant Health, Inivata, Janssen, Merck, Novartis, Pfizer, Roche, Takeda				CME lectures (travel and/or honoraria): AstraZeneca, Bristol Myers Squibb, Eisai, Janssen, Merck, Novartis, Sanofi, Takeda
Jyoti Malhotra, MD, MPH	Bristol Myers Squibb, Daiichi-Sankyo, Beyond Spring Pharma	AstraZeneca, Mirati, Oncocyte, Sanofi, Bioatla, Catalyst Pharma, Takeda, Regeneron, AbbVie, Janssen, Jazz Pharma			
Erminia Massarelli, MD, PhD, MS	AstraZeneca, Merck, Bristol Myers Squibb, Genentech, GSK, Pfizer, Tessa Therapeutics	AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Fusion Pharmaceuticals, Iovance Biotherapeutics, Janssen, Mirati Therapeutics, Sanofi	AstraZeneca, Eli Lilly and Company, Mirati Therapeutics, Takeda		
Tony S. Mok, MD, FRCPC, FASCO	Paid to Institution: AstraZeneca, Bristol Myers Squibb, EMD Serono, G1 Therapeutics, Merck, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals Group, Takeda, Xcovery Holdings	AbbVie, ACEA Pharma, Adagene, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca, Bayer, BeiGene, BerGenBio, Berry Oncology, BI, Blueprint Medicines Corporation, Bowtie Life Insurance Company, Bridge Biotherapeutics, Bristol Myers Squibb, C4 Therapeutics, Cirina, Covidien, CStone Pharmaceuticals, Curio Science, D3 Bio, Da Volterra, Daiichi Sankyo, Eisai, Elevation Oncology, Eli Lilly and Company, Roche, Genentech, Fishawack Facilitate, G1 Therapeutics, geneDecode, Gilead Sciences, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Hutchmed, Ignyta, Incyte, Inivata, IQVIA, Janssen, Lakeshore Biotech, Loxo Oncology, Lucence Health, Lunit USA, Medtronic, Merck Serono, Mirati Therapeutics, MiRXES, MORE Health, MSD, Novartis, Omega Therapeutics, OrigiMed, OSE Immunotherapeutics, Pfizer, Prenetics, priME Oncology, Puma Biotechnology, Qiming Development (HK) Ltd, Simcere of America Inc, Summit Therapeutics, Synergy Research Group, Takeda, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation		Stock shareholder: AstraZeneca, Aurora Tele-Oncology, Biolidics, Hutchmed, Prenetics Stock options: Bowtie Life Insurance Company, D3 Bio, Lakeshore Biotech, Loxo Oncology, Lunit USA, Virtus Medical Group	Speaker's fees received from: ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca, BeiGene, BI, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Fishawack Facilitate, inMed Communications, Janssen Pharmaceutica NV, Jiahui Holdings Co Limited, LiangYiHui Healthcare, Eli Lilly and Company, Lucence Health, MD Health Brazil, Merck, Merck Sharp & Dohme, MiRXES, Novartis, OrigiMed, P. Permyer SL, Pfizer, priME Oncology, Roche Pharmaceuticals/Diagnostics/Foundation One, Sanofi-Aventis, Shanghai BeBirds Translation & Consulting Co, Shanghai Promedican Pharmaceuticals Co, Ltd, Taiho Pharmaceutical Co, Ltd, Takeda, Touch Independent Medical Education Ltd Advisory board: AbbVie, ACEA Pharma, Amgen, AstraZeneca, BerGenBio, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bowtie Life Insurance Company, Bristol Myers Squibb, C4 Therapeutics, Covidien, CStone Pharmaceuticals, Curio Science, D3 Bio, Daiichi Sankyo, Eisai, Fishawack Facilitate, G1 Therapeutics, geneDecode (uncompensated), Gilead Sciences, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Hutchmed, Ignyta, Incyte, Inivata, IQVIA, Janssen, Lakeshore Biotech, Eli Lilly and Company, Lunit USA, Loxo Oncology, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MiRXES, Novartis, OrigiMed, Pfizer, Puma Biotechnology, Roche/Genentech, Regeneron Pharmaceuticals, Sanofi-Aventis R&D, SFJ Pharmaceuticals Group, Simcere of America Inc, Takeda, Vertex Pharmaceuticals, Virtus Medical Group, Yuhan Corporation Board of directors/ leadership roles (remunerated): AstraZeneca, Aurora Tele-Oncology, HutchMed Travel sponsorship: AbbVie, AstraZeneca, Daiichi Sankyo, MiRXES, Novartis, Roche, Pfizer
Misako Nagasaka, MD, PhD		Caris Life Sciences		Blueprint Medicines Corporation, Janssen, Mirati Therapeutics, Takeda	Advisory boards: AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Genentech, Novartis, Pfizer Travel support: AnHeart Therapeutics

ACTIVITY OVERVIEW

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Solange Peters, MD, PhD	PI in trials sponsored by Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, GSK, Merck Sharp & Dohme, Roche/Genentech (financial support to institution)	Consultation/Advisory role: AbbVie, Amgen, Arcus Biosciences, AstraZeneca, Bayer, BeiGene, BerGenBio, Biocartis, BioInvent International, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly and Company, Elsevier, F-Star Therapeutics, Fishawack, Foundation Medicine, Genzyme, Gilead Sciences, GSK, Illumina, Imedex, IQVIA, Incyte, Ipsen, iTeos Therapeutics, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack Pharmaceuticals, Mirati Therapeutics, Novartis, Novocure, Pfizer, PharmaMar, Phosplatin Therapeutics, Regeneron Pharmaceuticals, RMEI Medical Education, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda, Vaccibody			All fees to institution
Karen L. Reckamp, MD, MS	Research funding to institution: Blueprint Medicines Corporation, Calithera Biosciences, Daiichi Sankyo, Elevation Oncology, Genentech, Janssen	Consultant to self: Amgen, AstraZeneca, Blueprint Medicines Corporation, Daiichi Sankyo, Eli Lilly and Company, EMD Serono, Genentech, GSK, Janssen, Mirati Therapeutics			
Edgardo S. Santos Castillero, MD, FACP		AbbVie, AstraZeneca, Genentech, Regeneron Pharmaceuticals, Sanofi	Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, G1 Therapeutics, Genentech, Jazz Pharmaceuticals, Merck, Mirati Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sobi, Takeda		
Masahiro Tsuboi, MD, PhD	(To facilities) AstraZeneca, BMG Pharma, Bristol Myers Squibb, Eli Lilly Japan, MiRXES, MSD, Novartis, Ono Pharmaceutical	(Advisory role) AstraZeneca, BMG Pharma, Bristol Myers Squibb, Eli Lilly Japan, MiRXES, MSD, Novartis, Ono Pharmaceutical			Honorarium for lecture: Johnson & Johnson Japan, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Medtronic Japan, MSD, Novalis, Ono Pharmaceutical, Taiho Pharmaceutical Co, Ltd
Heather A. Wakelee, MD, FASCO	AstraMedimmune, Bayer, BMS, Clovis Oncology, Helsinn Group, Merck, Roche/Genentech, Seagen, Xcovery Holdings	Mirati Therapeutics— DSMB service			

Hatim Husain, MD will provide relevant financial relationships prior to the presentation.

PER has identified and mitigated all COI prior to the start of this activity by using a multistep process.

**Information accurate at time of printing.*

ACTIVITY OVERVIEW

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Co-Chairs



David R. Gandara, MD

Chief Medical Officer, International Society of Liquid Biopsy
Co-Director, Center for Experimental Therapeutics in Cancer
Senior Advisor to the Director
UC Davis Health Comprehensive Cancer Center
Adjunct Clinical Professor, Translational and Clinical Research Program
Professor Emeritus
University of Hawaii Cancer Center
Sacramento, CA



Heather A. Wakelee, MD, FASCO

Interim Medical Director, Deputy Director
Stanford Cancer Institute
Professor of Medicine
Chief, Division of Oncology
Stanford University School of Medicine
President, International Association for the Study of Lung Cancer
Stanford, CA



Roy S. Herbst, MD, PhD

Deputy Director, Chief of Medical Oncology
Director, Center for Thoracic Cancers
Yale Cancer Center and Smilow Cancer Hospital
Assistant Dean for Translational Research
Ensign Professor of Medicine
Professor of Pharmacology
Yale School of Medicine
New Haven, CT

FACULTY

Faculty



Maria E. Arcila, MD
Director, Diagnostic Molecular Pathology
Laboratory
Memorial Sloan Kettering Cancer Center
New York, NY



Paul Baas, MD, PhD
Thoracic Oncologist
Chief, Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, NL



Leah M. Backhus, MD, MPH, FACS
Associate Professor of Cardiothoracic
Surgery
Stanford University
Chief, Thoracic Surgery
Palo Alto Veterans Affairs
Stanford, CA



Lyudmila Bazhenova, MD
Clinical Professor of Medicine
Thoracic Oncologist
Director, Hematology Oncology Training
Program
Lung Cancer Unit Leader
UC San Diego Moores Cancer Center
La Jolla, CA



Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical
Oncology
Professor, Department of Hematology/
Oncology
Co-Director, Immune Monitoring Facility
Fox Chase Cancer Center, Temple Health
Philadelphia, PA



David P. Carbone, MD, PhD
Director
James Thoracic Oncology Center
Professor
The Ohio State University Comprehensive
Cancer Center
Columbus, OH



David T. Cooke, MD, FACS
Professor and Founding Chief, Division of
General Thoracic Surgery
Director, General Thoracic Surgery Robotics
Program
Program Director, Cardiothoracic Surgery
Fellowship
UC Davis Health
Sacramento, CA



Megan E. Daly, MD
Professor of Clinical Radiation Oncology
Associate Director, Clinical Research
Jennifer Rene Harmon Tegley and Elizabeth
Erica Harmon
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA



Millie Das, MD
Chief, Oncology
VA Palo Alto Health Care System
Clinical Associate Professor
Stanford Cancer Center
Palo Alto, CA



Deborah B. Doroshov MD, PhD
Assistant Professor of Medicine
Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai
New York, NY

FACULTY



Narjust Florez, MD
Associate Director, Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
JAMA Network
Boston, MA



Jonathan Goldman, MD
Director, Clinical Trials in Thoracic Oncology
Associate Director, Early Drug Development
Associate Professor of Medicine, Hematology/Oncology Division
UCLA Health
Los Angeles, CA



Fred R. Hirsch, MD, PhD
Executive Director, Center for Thoracic Oncology
Associate Director, Biomarker Discovery
Tisch Cancer Institute at Mount Sinai
Cancer
Professor of Medicine
Joe Lowe and Louis Price Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY



Hatim Husain, MD
Associate Professor of Medicine
UC San Diego Health
San Diego, CA



Pasi A. Jänne, MD, PhD
Director, Lowe Center of Thoracic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA



Karen Kelly, MD
Chief Executive Officer
International Association for the Study of Lung Cancer
Denver, CO



Edward S. Kim, MD, MBA, FACP, FASCO
Physician-in-Chief
City of Hope Orange County
Vice Physician-in-Chief
City of Hope National Medical Center
Duarte, CA



Corey J. Langer, MD, FACP
Director, Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA



Primo N. Lara, Jr, MD
Director
UC Davis Comprehensive Cancer Center
Executive Associate Dean for Cancer Programs
Professor of Medicine
UC Davis Health Comprehensive Cancer Center
Sacramento, CA



Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Lung Site Lead, Medical Oncology
Princess Margaret Cancer Centre
Toronto, ON



Jyoti Malhotra, MD, MPH
Associate Professor, Medical Oncology & Therapeutics Research
Director, Thoracic Medical Oncology
City of Hope Orange County
Irvine, CA



Erminia Massarelli, MD, PhD, MS
Section Chief, Thoracic Oncology
Co-Director, Lung Cancer and Thoracic
Oncology Program
Associate Professor, Department of
Medical Oncology & Therapeutics
Research
City of Hope
Duarte, CA



Tony S. Mok, MD, FRCPC, FASCO
Chairman, Department of Clinical
Oncology
Li Shu Fan Professor of Clinical Oncology
The Chinese University of Hong Kong
Sha Tin, HK
Misako Nagasaka, MD, PhD
Associate Clinical Professor, Division of
Hematology/Oncology
University of California, Irvine
Orange, CA



Solange Peters, MD, PhD
Full Professor
Medical Oncology Director, Oncology
Department
University Hospital of Lausanne
Lausanne, CH



Karen L. Reckamp, MD, MS
Director, Medical Oncology
Associate Director, Clinical Research
Medical Oncology Director, Lung Institute
Clinical Professor, Department of
Medicine
Cedars-Sinai Cancer
Los Angeles, CA



Edgardo S. Santos Castellero, MD, FACP
Associate Clinical Professor
Florida Atlantic University
Treasurer, FLASCO
President, FLASCO Foundation
Boca Raton, FL



Nicholas Stollenwerk, MD
Associate Clinical Professor, Internal
Medicine, Pulmonary and Critical Care
Medicine
Medical Director, Pulmonary Services
Laboratory
Associate Program Director, Pulmonary
and Critical Care Fellowship Program
Course Instructor of Record, Medical
Student Pulmonary Pathophysiology
UC Davis Health
Sacramento, CA



Masahiro Tsuboi, MD, PhD
Department Director and Chief,
Department of Thoracic Surgery
National Cancer Center Hospital East
Kashiwa, JP

Save the Date!

18th Annual New York
LUNG CANCERS
SYMPOSIUM[®]

NOVEMBER 11, 2023

EXCLUSIVELY IN-PERSON

NEW YORK HILTON MIDTOWN
NEW YORK, NY

50% OFF
HCP REGISTRATION!
REGISTER WITH CODE: **ILCC50**

For more information, visit

gotoper.com/ny123

